June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
|Videos|February 12, 2022
The importance of hysteresis in glaucoma management
Author(s)David Hutton
Robert L. Stamper, MD, speaks with Ophthalmology Times®' David Hutton on intraocular pressure measurement, corneal elasticity, and why hysteresis is important for glaucoma management.
Advertisement
Robert L. Stamper, MD, speaks with Ophthalmology Times®' David Hutton on intraocular pressure measurement, corneal elasticity, and why hysteresis is important for glaucoma management.
Advertisement
Related to this article
Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Length and width, not thickness, emerge as key drivers of higher-order aberrations.
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
2
Duravyu misses noninferiority end point in phase 3 LUCIA wet AMD trial
3
Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA
4
Alvotech files first known aflibercept 8 mg biosimilar with EMA
5